Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Estrella Immunopharma, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2022
FY2024
FY2024
FY2025
Research and development
10.5
4.11
10.2
General and administrative
0.66
3.2
2.81
Operating expenses
11.1
7.31
13.1
Operating income
-0.25
-1.57
-11.1
-7.31
-13.1
Interest income
0
0.65
Pre-tax income
-0.25
-0.92
-11.1
-7.31
-13.1
Income tax
0
0.08
0
0
Net income
-0.25
-1
-11.1
-7.31
-13.1
EPS, basic
-36.35
-0.27
-0.35
EPS, diluted
-36.35
-0.27
-0.35
Shares, basic (weighted)
1.18
0.31
27.1
36.8
Shares, diluted (weighted)
1.18
0.31
27.1
36.8
Balance sheet
FY2021
FY2022
FY2024
FY2024
FY2025
Cash and equivalents
0.48
0.04
2.48
4.17
1.38
Receivables
0.27
Other current assets
0.14
0.01
0.09
0.29
0.29
Total current assets
0.62
0.05
2.75
4.45
1.68
Total assets
45.8
9.72
3.03
4.45
3.18
Accounts payable
0
0.33
0.44
Accrued liabilities
0.12
Total current liabilities
0.07
1.07
9.76
0.18
13.5
Other non-current liabilities
0.01
Total liabilities
1.62
2.65
9.77
0.18
13.5
Paid-in capital
0.45
24.1
27.2
Retained earnings
-1.01
-2.26
-12.2
-19.5
-37
Treasury stock
-0.35
-0.6
Shareholders' equity
-1.01
-6.48
-11.7
4.27
-10.4
Total equity
-1.01
-6.48
-11.7
4.27
-10.4
Total liabilities and equity
45.8
9.72
3.03
4.45
3.18
Shares outstanding
1.42
1.42
0.98
36.6
Cash flow statement
FY2021
FY2022
FY2024
FY2024
FY2025
Net income
-0.25
-1
-11.1
-7.31
-13.1
Stock-based compensation
0.41
1.19
0.62
Deferred income tax
0.03
Change in payables
0.33
Cash from operations
-0.32
-1.04
-1.34
-16.1
-1.79
Cash from investing
-45.2
36.2
-0.27
4.96
Debt issued
10
Stock issued
0.03
2.4
Share buybacks
-0.35
-0.03
Cash from financing
46
-35.6
12.8
2.25
Net change in cash
0.48
-0.44
-1.61
1.69
0.47
Interest paid
0
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.48 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-548.7%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets CAGR, 3y
-31.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.20x
Current assets / current liabilities.
Quick ratio
0.01x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.01x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.22
Cash from operations / diluted weighted shares.
Book value per share
-$0.17
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-47.9%
Net income / market cap (the inverse of P/E).
Was Estrella Immunopharma, Inc. profitable in fiscal 2025?
No. It reported a net loss of $13.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.